

Cognitive effects of cell-derived and synthetically derived A β oligomers

Miranda N. Reed^{a,b}, Jacki J. Hofmeister^c, Lisa Jungbauer^d, Alfred T. Welzel^e,
Chunjiang Yu^d, Mathew A. Sherman^{a,b}, Sylvain Lesné^{a,b}, Mary Jo LaDu^d,
Dominic M. Walsh^e, Karen H. Ashe^{a,b,c}, James P. Cleary^{b,c,f,*}

^a N. Bud Grossman Center, University of Minnesota, Minneapolis, MN 55455, United States

^b Departments of Neurology, University of Minnesota, Minneapolis, MN 55455, United States

^c Geriatric Research, Education and Clinical Center, Veterans Affairs Medical Center, Minneapolis, MN 55417, United States

^d Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL 60607, United States

^e Laboratory for Neurodegenerative Research, Conway Institute, University College Dublin, Dublin 4, Ireland

^f Departments of Psychology, University of Minnesota, Minneapolis, MN 55455, United States

Received 14 April 2009; received in revised form 27 October 2009; accepted 10 November 2009

Available online 19 January 2010

Abstract

Soluble forms of amyloid- β peptide (A β) are a molecular focus in Alzheimer's disease research. Soluble A β dimers (\approx 8 kDa), trimers (\approx 12 kDa), tetramers (\approx 16 kDa) and A β *56 (\approx 56 kDa) have shown biological activity. These A β molecules have been derived from diverse sources, including chemical synthesis, transfected cells, and mouse and human brain, leading to uncertainty about toxicity and potency. Herein, synthetic A β peptide-derived oligomers, cell- and brain-derived low- n oligomers, and A β *56, were injected intracerebroventricularly (icv) into rats assayed under the Alternating Lever Cyclic Ratio (ALCR) cognitive assay. Cognitive deficits were detected at 1.3 μ M of synthetic A β oligomers and at low nanomolar concentrations of cell-secreted A β oligomers. Trimers, from transgenic mouse brain (Tg2576), did not cause cognitive impairment at any dose tested, whereas A β *56 induced concentration-dependent cognitive impairment at 0.9 and 1.3 μ M. Thus, while multiple forms of A β have cognition impairing activity, there are significant differences in effective concentration and potency. Published by Elsevier Inc.

Keywords: Alzheimer's disease; Amyloid- β peptide; A β ; Oligomers; Cognition

1. Introduction

Recent Alzheimer's disease (AD) research has focused on non-fibrillar soluble amyloid- β protein (A β) as a cause of cognitive symptoms associated with the disease. Previously, the large aggregated fibril plaques that pathologically characterize the disease were assumed to be the primary toxins. However, poor correlations between human plaque load and cognitive symptoms suggested that a non-fibrillar A β assembly may contribute to the synaptic loss and cognitive deficits characteristic of AD (Walsh and Selkoe, 2007). Subsequently, a soluble form of synthetic A β _(1–42) was shown

to impair long-term potentiation (LTP) and induce cell death (Lambert et al., 1998). Atomic force microscopy (AFM) analysis revealed pseudo-spherical assemblies (2–4 nm) which were free of fibrillar assemblies (Dahlgren et al., 2002; Lambert et al., 1998; Stine et al., 2003). Further analysis showed these soluble A β ₄₂ assemblies exhibited neurotoxicity (Manelli et al., 2007) and reduced neuronal excitability in hippocampal neurons (Trommer et al., 2005; Yun et al., 2006).

In 2002 soluble oligomers derived from the culture medium of cells transfected with a mutant human form of APP (7PA2 cells) were isolated and shown to inhibit LTP while monomers of cell-derived A β did not (Walsh et al., 2002). Subsequently, a mixture of dimers and trimers isolated from the conditioned media (CM) of these cells was shown to disrupt memory for learned behavior (Cleary et al., 2005). In 2006, Lesné et al. (2006) showed that

* Corresponding author at: GRECC 11G, VA Medical Center, 1 Veterans Drive, Minneapolis, MN 55417, United States. Tel.: +1 612 467 3341; fax: +1 612 725 2084.

E-mail address: clear006@umn.edu (J.P. Cleary).

a 56 kDa form of A β purified from Tg2576 mouse brain disrupted maze performance when injected into the lateral ventricle of rats. Recently, soluble A β dimers, isolated from cerebral cortex of AD subjects, were shown to inhibit LTP, reduce dendritic spine density in rodent hippocampus, and disrupt memory in normal rats (Shankar et al., 2008).

Several crucial questions about the toxicity and relevance of different forms of A β have remained unresolved. A β oligomer source, size, concentration and production methods have varied significantly across laboratories, making it difficult to draw firm conclusions about the relative toxicity of various soluble A β assemblies. Soluble A β preparations have been defined by numerous methods, including isolation technique (primarily size-exclusion chromatography, SEC), size estimation by SDS or native PAGE, conformation-specific antibodies reactivity, and several imaging techniques. In addition, A β molecules have been derived from cultured cells, transgenic mouse brain, human brain, and synthetic A β protein. Crucial issues include questions regarding the similarities and differences between synthetic and living cell-produced A β , and their relative toxicity or potencies under the same experimental conditions. In the current study, we make side-by-side comparisons of three different A β assemblies, including oligomeric assemblies formed by chemically synthesized A β_{42} , SDS-stable low-*n* oligomers from transfected cells, and SDS-stable low- and high-*n* oligomers from transgenic mouse brain. Preparations of the differently sized and sourced assemblies were injected into the lateral ventricle of awake rats and tested under a behavioral assay previously shown sensitive to the subtle impairments of low-*n* oligomers (Cleary et al., 2005; Townsend et al., 2006a).

2. Methods

2.1. Cell-derived soluble A β from APP over-expressing cultured cells

Chinese hamster ovary cells that stably express human APP₇₅₁ incorporating the familial Alzheimer's disease mutation V717F (Koo and Squazzo, 1994; Podlisny et al., 1995) were used as a source of A β monomer and low-*n* oligomers. These cells, referred to as 7PA2, were cultured in 10 cm dishes with Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, 100 units/ml penicillin, 100 μ g/ml streptomycin, 2 mM L-glutamine and 200 μ g/ml G418. Upon reaching 90–100% confluency, cells were washed with 5 ml of glutamine- and serum-free DMEM and incubated for approximately 15 h in 5 ml of the same plain DMEM. Conditioned media (CM) was collected and spun at 200 \times g and 4 $^{\circ}$ C for 10 min to remove cellular debris. 7PA2 CM was concentrated approximately 10-fold using a Centriprep Ultracel YM-3 filter (Millipore, Carrigtwohill, Co. Cork, Ireland).

2.1.1. Size-exclusion chromatography

Size-exclusion chromatography was used to facilitate isolation of A β monomers, dimer-enriched and trimer-enriched fractions. One milliliter of concentrate was chromatographed on a Superdex 75 10/300 GL column (Amersham Biosciences AB, Uppsala, Sweden) and run at a flow rate of 0.8 ml/min using an AKTA purifier (GE Healthcare Biosciences AB, Uppsala, Sweden) and eluted with 50 mM ammonium acetate pH 8.5 in 1 ml fractions. To identify A β -containing fractions aliquots of each fraction (300 μ l) were lyophilized and used for Western blot analysis. The remaining 700 μ l was immediately frozen and stored at -80° C pending use in the injection regimen described below. Lyophilized fractions were resuspended in 20 μ l 2 \times sample buffer and electrophoresed on a 10–20% Tris–tricine gel (Invitrogen, Carlsbad, CA, USA). Proteins were transferred onto 0.2 μ m Optitran reinforced nitrocellulose (Whatman GmbH, Dassel, Germany) and immuno-blotted using the monoclonal antibodies 2G3 and 21F12 each at a concentration of 1 μ g/ml. These antibodies recognize the C-terminus of A β_{40} (2G3) and A β_{42} (21F12). Immunoreactive bands were detected using an Odyssey Infrared Imaging System model 9120 (LI-COR Biosciences, Lincoln, NE, USA).

2.1.2. Protein concentrations

The total A $\beta_{40/42}$ in concentrated 7PA2 CM (Fig. 1a and b) has been shown to be approximately 5–10 nM (Walsh et al., 2002; Cleary et al., 2005). The concentration of total A $\beta_{40/42}$ in the enriched SEC fractions containing soluble A β oligomers (Fig. 1c and d) was estimated from the relative amounts of A β trimers and dimers to synthetic A β peptide standards using densitometry analyses of the Western blots (Supplementary Fig. 1). Once respective levels of low-*n* A β oligomers were known, monomeric A β was measured by A β ELISA to estimate the relative amounts of A β trimers and dimers. Monomeric levels were used because it has been shown that ELISA does not reliably detect oligomeric assembly forms of A β (Morishima-Kawashima and Ihara, 1998; Sten et al., 2005), while it does provide a robust indicator of A β monomer concentration (Walsh et al., 2000, 2002).

2.2. Brain-derived soluble A β from Tg2576 APP over-expressing transgenic mice

2.2.1. Immunoaffinity chromatography

Forebrains were lysed in RIPA buffer and ultracentrifuged as previously described (Lesné et al., 2006). Proteins were incubated overnight with columns packed with 2 mg of purified 4G8 or 6E10 antibody. Columns were created by crosslinking antibodies to the Affi-Prep protein A resin (Bio-Rad Laboratories). Captured proteins were eluted in acidic buffer (pH 3). Trimers were purified from extracellular-enriched (EC) fractions and A β *56 from EC/RIPA fractions.




Fig. 1. (a) IP/Western blot analysis of 7PA2 and CHO-CM reveals the presence of A β monomer (M), dimer (D) and trimer (T) in 7PA2 CM, but not in CHO-CM. The polyclonal antibody AW38 was used for IP and the anti-A β antibodies 2G3 and 21F12 were used for immunoblotting. Molecular weight standards are shown at left. (b) Mean approach and perseveration errors under ALCR, expressed as a percentage of their respective baseline rates (100%), after rats received injections of CHO, and serial dilutions of 7PA2 CM. (c) SEC of 7PA2 CM results in the elution of A β species in monomer-enriched, dimer-enriched, and trimer-enriched fractions. A β species were detected using 2G3 and 21F12. Molecular weight standards are shown on the left. Values are means \pm the standard error of the mean. (d) Mean approach and perseveration errors under ALCR, expressed as a percentage of their respective baseline rates (100%), after rats received the monomer-enriched, dimer-enriched, and trimer-enriched fractions. Significant differences ($p < 0.05$) between baseline and mean error value are indicated by an asterisk.

2.2.2. Size-exclusion chromatography

Immunoaffinity purified protein extracts were loaded on Tricorn Superdex[®] 75 columns (GE Healthcare Life Sciences) and run at a flow rate of ~ 0.3 ml/min. Fractions of 250 μ l of eluate in 50 mM ammonium acetate, pH 8.5, were used in rat application experiments, or were concentrated using a vacuum system (VacuFuge[™], Brinkmann-Eppendorf) and analyzed by silver staining and Western blot.

2.2.3. Protein concentrations

Protein amounts were determined using the BCA Protein Assay (Pierce). All supernatants were ultra-centrifuged for 20 min at 100,000 rpm. Finally, before analysis, fractions were immunodepleted by sequentially incubating them for 1 h at room temperature with 100 μ l of Protein A-Sepharose, Fast Flow[®] followed by 100 μ l of Protein G-Sepharose, Fast Flow[®] (GE Healthcare Life Sciences). For confirming protein concentrations following SEC, 10 μ l of each




Fig. 2. (a) Aβ species were purified from the total protein of the radioimmune precipitation assay buffer (RIPA) soluble fraction using immunoaffinity purification columns (IPC) packed with 200 mg of 6E10 or 4G8 antibodies. (b) Immunoaffinity purified protein extracts isolated with 6E10 were loaded on a Superdex 75 column and Western blotted with 6E10 or silver stained to yield fractions containing trimers or Aβ*56. (c) Mean approach and perseveration errors, expressed as a percentage of their respective baseline rates (100%), after rats received injections of 0.4–1.3 μM trimers or 0.4–1.3 μM Aβ*56 (*p < 0.05). Error bars represent SEM.

fraction was incubated overnight at 37 °C to increase sensitivity.

The concentration of Tg2576-derived Aβ oligomers was determined following affinity purification (Fig. 2a) coupled to size-exclusion chromatography (Fig. 2b). As indicated, only one protein was predominantly found in corresponding fractions, allowing for the direct determination of protein concentration by BCA assay.

2.2.4. Silver staining

Following SEC fractionation and SDS-PAGE, gels were stained using the SilverXpress® Silver Staining Kit

(Invitrogen™ Life Technologies, USA) with an adapted protocol in which all washing steps were repeated 4 times and gels were incubated in developing solution for 15 min.

2.2.5. Western blot analysis of SDS-PAGE

Electrophoreses were done on pre-cast 10–20% SDS-polyacrylamide Tris–tricine gels (Bio-Rad). Thereafter, proteins were transferred to a 0.2 μm nitrocellulose membrane (Bio-Rad) at 400 mA for 180 min. Nitrocellulose membranes were boiled for 2 × 4 min in PBS and blocked in TTBS (Tris-buffered saline–0.1%Tween®20) containing 5% bovine serum albumin (BSA) plus 0.05% cold water

fish skin gelatin (Sigma), and probed with appropriate antisera/antibodies diluted in 5%BSA–0.05%Gelatin TTBS. Primary antibodies were probed with anti-IgG immunoglobulins conjugated with biotin followed by Neutravidin[®]–HRP (Pierce) to amplify the signal. All blots were finally developed with an enhanced chemiluminescence (ECL) Western blotting detection system (Supersignal Pico Western system, Pierce).

2.3. Soluble A β derived from synthetic A β ₄₂

2.3.1. Preparation

Synthetic A β ₄₂ peptide (California Peptide, Napa, CA) was prepared as previously described to generate A β ₄₂ oligomers (Stine et al., 2003). Briefly, peptide was dissolved to a final concentration of 1 mM in hexafluoroisopropanol (HFIP) (Sigma–Aldrich, St. Louis, MO), aliquoted into microcentrifuge tubes, the HFIP evaporated, and the peptide stored at –20 °C as an HFIP film. The aliquoted peptide was resuspended with anhydrous DMSO to 5 mM, diluted to 100 μ M with cold phenol red-free F-12 cell culture media (with L-glutamine; Promocell, Heidelberg, Germany), vortexed for 15 s, and incubated at 4 °C for 24 h prior to use.

For synthetic A β oligomers (Fig. 3), the indicated concentration refers to the amounts of synthetic A β ₄₂ peptide used to create each solution at $t=0$. As shown in Fig. 3a, we exclusively detected species ~13–15 kDa in freshly prepared A β oligomers solutions.

2.3.2. Western blot analysis of SDS-PAGE

Gel electrophoresis and Western blot analysis were performed as described previously (Dahlgren et al., 2002). Briefly, unheated samples were diluted in NuPage LDS sample buffer, separated by SDS-PAGE on a 4–12% NuPage Bis–Tris gel (Invitrogen), and transferred to 0.2 μ m polyvinylidene difluoride membranes. Membranes were blocked for 1 h in a solution of 5% nonfat dry milk in Tris-buffered saline containing 0.0625% Tween 20. Blots were then incubated with 6E10 (1:7000), a mouse monoclonal A β antibody to residues 1–16 (Signet, Dedham, MA). For detection, the membrane was incubated with horseradish peroxidase-conjugated rabbit-anti-mouse IgG (1:5000), developed using enhanced chemiluminescence (PerkinElmer), and exposed to film. Molecular mass was estimated using MultiMark pre-stained molecular weight markers (Invitrogen).

2.3.3. Size-exclusion chromatography

Aliquots of synthetic A β ₄₂ under oligomer-forming conditions (100 μ M) were further diluted to 500 μ l in F12 media at $t=0$ (e.g., immediately after dilution from DMSO; 2 μ M) or $t=24$ (following oligomer formation; 1.2 μ M) and loaded on Tricorn Superdex[®] 75 columns (GE Healthcare Life Sciences) connected to a BioLogic DuoFlow system (BioRad Laboratories, Hercules, CA) and run at a flow rate of 0.3 ml/min. Fractions of 250 μ l of eluate in 50 mM ammo-

nium acetate, pH 8.5, were collected and analyzed by dot blot (5 μ l) and Western blot (35 μ l) using anti-A β antibody 6E10.

2.3.4. Atomic force microscopy (Supplementary Fig. 2)

Peptide solutions were characterized as described previously (Stine et al., 2003) using a NanoScope IIIa scanning probe work station equipped with a MultiMode head using a vertical engage E-series piezoceramic scanner (Veeco, Santa Barbara, CA). AFM probes were single-crystal silicon microcantilevers with 300-kHz resonant frequency and 42 N/m spring constant model OMCL-AC160TS-W2 (Olympus). Samples were imaged under dry helium. Ten microliters of sample solution (diluted from 100 to 10 μ M using 0.02- μ m filtered MilliQ H₂O) was spotted on freshly cleaved mica (pre-spotted with 1 μ l of 1 M HCl), incubated at room temperature for 1.5 min, rinsed with 0.02- μ m filtered (Whatman Anotop 10) deionized water (18 M Ω MilliQ, Millipore), and blown dry with tetrafluoroethane (CleanTex MicroDuster III). Image data were acquired at scan rates between 1 and 2 Hz with drive amplitude and contact force kept to a minimum. Data were processed to remove vertical offset between scan lines by applying first-order xy plane fit and zero order flattening polynomials using Nanoscope software (Version 5.34, Veeco).

2.4. Alternating Lever Cyclic Ratio cognitive assay

Forty-one male Sprague–Dawley rats were used for all comparisons of A β assemblies, except for assessment of A β *56, for which the original group size was 24 at the start of that experiment. All rats were approximately 120 days old, weighing 300–350 g at the beginning of the experiment and were housed individually with free access to water. Rats were maintained at 90–95% of their free-feeding weights.

Behavioral training and testing was carried out in a two-lever rat test chamber (model E10, Coulbourn Instruments, Inc.) enclosed within a sound-attenuating compartment complete with ventilating fan and white noise. Each station has a house light, two levers, a feeding aperture for pellet delivery situated midway between levers, and stimulus signalling lights above each lever. Food reinforcement consisted of a 45-mg sucrose pellet, and a food tray light and audible pellet-dispenser click signalled food delivery. Experimental sessions were computer controlled, and data were collected automatically (MED PC; Med Associates).

For training, behavioral sessions were conducted 5 days a week. Rats were first trained to press both levers for food reinforcement. Over approximately 20–30 sessions, the ALCR procedure was introduced and required responses-per-reinforcer criteria were slowly increased toward the final requirements (see below).

The ALCR test has been described in detail previously (Cleary et al., 2005; Richardson et al., 2002). Briefly, under this assay rats must learn a complex sequence of lever-pressing demands in a two-lever experimental chamber. In a

Fig. 3. (a) Representative Western blots of A β 42 oligomers separated by SDS-PAGE and probed with 6E10. The figure shows 0- and 24-h oligomers (lanes 1 and 2, respectively). (b) Densitometry analysis from dot blots probed with 6E10 following SEC fractionation. Two major peaks were detected and corresponding fractions were also subjected to SDS-PAGE analyses (inserts show Western blots of indicated fractions using 6E10). (c) Mean approach and perseveration errors under ALCR, expressed as a percentage of their respective baseline rates (100%), after rats received injections of 0.4–1.3 μ M of synthetic A β . Values are means \pm the standard error of the mean. Significant differences ($p < 0.05$) between baseline and mean error value are indicated by an asterisk.

simple measure of what may be termed short-term memory, subjects must alternate to the other lever after pressing one lever enough to satisfy the pressing requirement and getting food reward. However, the requirements are more complex than simple alteration. The exact number of presses required for each food reward changes, increasing from 2 responses per food pellet up to 56 presses per food pellet, and then decreasing back to 2 responses per pellet. Intermediate values are based on the quadratic function, $x^2 - x$. One cycle is an entire ascending and descending sequence of lever press requirements (e.g., 2, 6, 12, 20, 30, 42, 56, 56, 42, 30, 20, 12, 6, and 2 presses per food reward). Six cycles are presented dur-

ing each daily session. The session ended after 6 cycles were completed or after 2 h. Behavioral sessions were conducted 7 days per week during compound testing. Rats received approximately 40 sessions prior to surgery. Errors can be of two types. Approach errors are counted when a subject fails to alternate levers after being rewarded or switches from the correct lever to the incorrect lever before completing enough responses to get a reward on the correct lever. This type of simple alternation task is similar to other short-term memory tasks. Perseveration errors occur when the subject ‘perseveres’ on the incorrect lever after making an initial approach error. This type of error represents disruption of well-learned

behaviors as well as ‘rules of the game’ or reference memory (O’Hare et al., 1996).

2.5. Surgery and lateral ventricle cannula implantation

Rats were anesthetized with a 60 mg/kg of ketamine and 20 mg/kg xylazine. A 26-gauge cannula was implanted unilaterally in the lateral ventricle. Cannulae were capped with stylets that extended the length of the cannula. Half of the rats received left lateral ventricle cannulae implants and the other half received right ventricle cannulae implants. Rats were allowed to recover for 5 days following surgery at which point baseline error rates were re-established under ALCR.

2.6. Injection schedule, injectates and vehicles

Behavioral sessions were conducted 7 days per week, with test injection sessions typically occurring every 4 days. A *within-subjects experimental design* was employed in the current study. Under this design, all animals receive all treatments and the results under each test injection is compared to each animal’s own baseline performance. Each animal’s baseline performance is taken as the mean number of errors on 3 non-injection sessions contiguous to each test injection session. Due to the large number of icv injections undertaken for the current protocol, three groups of rats performing under ALCR were used to accommodate all necessary injections of A β and vehicles. The first group of rats received all doses of Tg2576 mouse brain-derived trimers, synthetic A β ₄₂ oligomers, and 7PA2 cell-derived SEC fractions. Under the within-subject design, each rat in this group received all concentrations of each type of these forms of A β . The next group of rats, running under an identical ALCR procedure, received all the dilutions of 7PA2 and CHO-CM. Again, all rats in this group received each dilution of 7PA2 CM and CHO. The final group received concentrations of A β *56 and appropriate vehicle injections. For this group, only a limited amount of A β *56 was available and thus some rats did not receive a particular concentration. Rats receiving a given concentration were determined randomly and, as above, all effects were determined by comparison to each rat’s mean baseline performance. All behavioral and injection procedures were exactly the same across all groups. To ensure that there were no residual effects of the injectate on the next day’s performance, baseline errors for the day prior to and the day after the injection were always compared using *t*-tests. Consistent with previous findings (Cleary et al., 2005), acute icv A β oligomer injections had no long lasting effects or carry over effects (data not shown).

All icv injections were 20 μ l, given to awake freely moving rats, over at least a 3 min period. After injections, the cannula was capped with a stylet, and the rat was placed in a holding cage for 2 h prior to behavioral assessment under ALCR. On non-injection days, rats were injected with 0.9% saline (20 μ l icv) or were subjected to “sham” injections. Rats were injected icv with saline prior to initial active compound

injections and approximately once every 2 weeks throughout the experiment. Sham injections, under which injectors were inserted into the cannulae, but no injection was given, were conducted on non-injection days throughout the experiment.

Rats were injected with CM or dilutions of CM (1:1, 1:3) from 7PA2 cells. As a negative control for impurities in culture medium, rats were injected with CM from wild type CHO cells not expressing human APP. Rats were also injected with Tg2576 brain-derived A β corresponding to a trimer (~14 kDa) and A β *56. Vehicle injections for Tg2576 brain-derived A β were ammonium acetate (50 mM) eluate from the SEC column devoid of protein by silver staining and BCA assay. A β assemblies prepared from synthetic A β ₄₂ were also tested. All injections were given 2 h prior to the beginning of behavioral sessions and, in all cases, a total volume of 20 μ l was injected. All rats received all injectates, except rats injected with Tg2576 brain-derived A β *56 or dilutions of 7PA2 CM, which were given to different groups of rats under the same experimental conditions. All experiments were done in accordance with guidelines of the Institutional Animal Care and Use Committee of the Minneapolis Veterans Affairs Medical Center.

2.7. Data analysis and statistics

Rats served as their own control in a within-subject design. Repeated analysis of variance (RMANOVA) was applied to approach and perseveration error data under ALCR assessment for all subjects except those receiving A β *56 and synthetically derived A β . Analysis of variance (ANOVA) was used for subjects receiving A β *56 because scarcity of material required that not all subjects received each concentration. Synthetically derived A β failed to pass Mauchly’s sphericity test, and therefore, a multivariate analysis of variance (MANOVA) was used. If overall F values were significant, paired two-tailed Student’s *t*-tests were used to test individual differences between means.

3. Results

3.1. Effects of cell-derived A β monomers, dimers and trimers

Conditioned medium (CM) from 7PA2 cells contains A β immunopositive species consistent with monomer, dimer and trimer (Fig. 1a) (Podlisny et al., 1995; Walsh et al., 2005, 2000). As with our previous findings (Cleary et al., 2005; Richardson et al., 2002), icv injection of concentrated conditioned media (CM) from 7PA2 cells produced significant increases in perseveration errors (RMANOVA $p=0.03$) under ALCR assessment (Fig. 1b), but approach errors were less affected (RMANOVA $p=0.09$). The concentrated 7PA2 CM (100%, Fig. 1b), containing approximately 5–10 nM of total A β (~8 ng/ml), increased perseveration errors to 162% of baseline error rate, which was significantly different from

the mean of baseline errors (post hoc $p=0.04$) and from the errors produced by CM from the non-transfected CHO cells (post hoc $p=0.03$). To explore a dose–effect relationship between 7PA2 CM and cognitive deficits, we diluted the stock CM with culture media (DMEM) and tested it under ALCR. A 1:1 dilution (Fig. 1b, 50%) of the stock CM with produced significantly increased perseveration errors (post hoc $p=0.05$ vs. baseline; $p=0.02$ vs. CHO), but the error increase after a 3:1 dilution did not reach statistical significance (Fig. 1b, 25%). Concentrations of 7PA2 CM above those used in the current study may result in significant changes in A β aggregation resulting in loss of solubility and decreased total protein in solution (Chen and Glabe, 2006).

In order to better assess whether a particular cell-derived A β species was responsible for the effects observed, the 7PA2 CM was fractionated by size-exclusion chromatography (SEC). This procedure yielded several fractions (Fig. 1c), including a trimer-enriched fraction containing primarily trimers (~12–14 kDa) as well as dimers (~8–9 kDa), a dimer-enriched fraction containing primarily dimers and some trimers, and a monomer-rich fraction containing mostly monomers (~4–5 kDa). Based on similarly generated fractions, we estimated the total A β in each of these fractions to be in the low nM range and containing 20–100 ng/ml A $\beta_{40/42}$ (Fig. 4, Fig. S1). A significant increase in the number of perseveration errors (planned comparison $p=0.01$) was seen following the injection of the dimer-enriched fraction (Fig. 1d). No significant increases in error rates were seen following injection of the trimer-enriched fraction, although this fraction showed some tendency to raise errors. The A β monomer fraction did not produce significant increases in any type of error under ALCR.




Fig. 4. Perseveration errors as a function of total A β (ng/ml) injected for each A β source, including CM from 7PA2 cells (7PA2 DEC), SEC enriched oligomers from 7PA2 CM (7PA2 Enriched), oligomeric A β chemically synthesized (Synthetic), SEC-isolated trimers from Tg2576 mouse brain (Tg2576 Trimers), and SEC-isolated A β^* 56 from Tg2576 mouse brain (Tg2576 A β^* 56). The X-axis represents estimated total A β . Asterisks denote errors under ALCR were significantly different from mean baseline performance ($p \leq 0.05$).

3.2. Effects of Tg2576 brain-derived trimers and A β^* 56

Tg2576 transgenic mice over-express the amyloid precursor protein (APP) and exhibit high levels of human A β species in brain (Hsiao, 1996). Following affinity capture using A β -targeting antibodies, all A β /APP derivatives from Tg2576 mouse brain were detected in the eluates (Fig. 2a). Captured Tg2576 mouse brain-derived A β assemblies were then resolved by molecular weight under SEC and electrophoresed as discrete bands on SDS-PAGE, which were recognized by the anti-A β monoclonal antibody 6E10 (Fig. 2b). A β trimers were tested at concentrations from approximately 0.4–1.3 μ M (~5.4–17.6 μ g/ml). Injections of Tg2576 brain-derived trimers produced weak effects, with neither approach errors nor perseveration errors reaching significance under RMANOVA (Fig. 2c). In contrast, injections of brain-derived A β^* 56 produced overall ANOVA values of $p=0.05$ for approach errors and $p=0.01$ for perseveration errors (Fig. 2c). Post hoc tests revealed significant differences from baseline at both 0.9 and 1.3 μ M (~48.8–70.4 μ g/ml) for approach ($p=0.03$ and $p=0.01$, respectively) and perseveration errors ($p=0.04$ and $p=0.02$, respectively).

3.3. Effects of synthetically derived A β oligomers

Solutions containing synthetic A β_{42} migrate as several discrete bands corresponding to monomers, trimers and tetramers when analyzed by SDS-PAGE/Western blot (Fig. 3a). After 24 h incubation under oligomer-forming conditions, analysis by atomic force microscopy (AFM) shows morphology consistent with that previously described for A β oligomers (Fig. S2a), lacking protofibril and fibrillar aggregates (Stine et al., 2003). Comparison of A β_{42} peptide solutions immediately after solubilizing ($t=0$) with that incubated for 24 h ($t=24$) clearly show larger structural oligomeric assemblies unique to the 24 h solution under SEC and AFM (Fig. 3b, Fig. S2). In contrast, SDS-PAGE/Western blot analysis of synthetic A β_{42} oligomers does not reflect the solution-state differences between the $t=0$ and the $t=24$ preparations (Bitan et al., 2005; Hepler et al., 2006), indicating these oligomers are not SDS-stable.

Under ALCR, injection of the synthetic A β_{42} oligomers that had been incubated for 24 h resulted in significant overall F values for both approach errors ($p=0.03$) and perseveration errors ($p=0.02$; Fig. 3c). At 1.3 μ M total A β_{42} (~5.8 μ g/ml), approach errors were increased to 123% of baseline error rate (post hoc $p=0.03$) and perseveration errors were increased to 150% of baseline errors (post hoc $p=0.02$). While lower concentrations showed some tendency to increase mean approach and perseveration errors, these effects did not reach significance.

In order to address the issue of relative potency we attempted to estimate the relative amounts of A β in each of our injected preparations. While estimation of unstable forms or solutions of diverse A β assemblies poses several problems (see Section 4), the amount of total A β in each preparation can

be estimated by a variety of means. Fig. 4 depicts estimates of the relative potency of the various A β solutions in terms of total A β injected at doses that disrupted cognitive performance. It is clear the cognitively disruptive concentrations of A β vary widely across the assembly forms tested, except in the case of effective concentrations of synthetic-derived and mouse brain-derived trimers (Fig. 4). As can be seen, A β from 7PA2 CM can effectively disrupt ALCR performance in the low nanomolar range, while A β *56 is effective in the micromolar range.

4. Discussion

Recently, low-*n* soluble A β oligomers have been implicated in the early symptoms of AD but supportive experimental assessments of its effects on brain function have been surprisingly sporadic. It has previously been shown that low molecular weight soluble assemblies of human A β secreted by 7PA2 cells potently inhibit hippocampal LTP *in vivo* and *in vitro* (Walsh et al., 2002; Wang et al., 2004). Subsequently, a mixture of 8 to 14 kDa human A β assemblies derived from 7PA2 cells and characterized as dimers and trimers, were fractionated by SEC and shown to significantly disrupted memory for learned behavior under ALCR (Cleary et al., 2005). Recently, Townsend et al. (2006b) reported that 7PA2-derived SEC-isolated A β trimers fully inhibited hippocampal LTP, while A β dimers and tetramers only partially inhibited LTP. In addition, A β dimers isolated from human AD cortex have also been shown to be toxic. When injected into rats, these dimers inhibited hippocampal LTP, decreased dendritic spine density, and interfered with learned avoidance memory (Shankar et al., 2008). The soluble assembly A β *56, produced from brains of transgenic mice over-expressing human APP was also shown to disrupt maze performance (Lesné et al., 2006).

Despite the progress noted above, variation in A β oligomer preparation, concentration, conformation, and its weak potency under behavioral assessment, have combined to impede analysis of its effects. In the current study, the potency of various oligomeric A β assemblies were addressed in a side-by-side comparison under the ALCR assay of cognitive function. First, the question of differences in potency between cell-derived A β and those derived under *in vitro* conditions from synthetic A β was addressed. In general, we have shown that both cell-derived A β oligomers, whether from APP over-expressing CHO cells (7PA2) or over-expressing APP transgenic mouse brain cells (Tg2576), as well as synthetically prepared A β assemblies, are capable of producing deficits in learned behavior. However, not all cell-derived A β oligomers proved equipotent. A β assemblies derived from 7PA2 cells, with molecular weights consistent with dimers and trimers, were highly potent at increasing errors of learned behavior at concentrations estimated to be in the low nanomolar range. Further, fractions from 7PA2 CM enriched with A β corresponding to dimers proved more potent than

trimer-enriched fractions, showing significantly increased perseveration errors under ALCR (Fig. 1d). While increases due to icv trimer-enriched fractions were not significant for either type of error, these fractions appeared to show higher amounts of sAPP alpha present at approximately 90–100 kDa (Fig. 1c). The sAPP alpha fragment has been shown to modulate calcium concentration and promote cell survival (Mattson et al., 1993). As has been consistently reported previously, SEC-isolated 7PA2 CM-derived monomers had no effect on errors under ALCR (Cleary et al., 2005; Townsend et al., 2006a). In contrast to the previous reports of effects on hippocampal LTP (Townsend et al., 2006b), we found that a SEC dimer-enriched 7PA2-derived A β fraction was more potent than the trimer-enriched fraction in disrupting learned behavior.

Among the neuron-derived A β assemblies isolated from the brains of APP over-expressing Tg2576 mice, the 56 kDa A β assembly A β *56 proved much more effective at increasing errors than did the SEC-isolated trimers. Although only a few concentrations of each A β preparation could be tested, A β *56 was the only A β oligomeric species tested that showed any relationship between concentration and effect (Fig. 2c). Because the Tg2576 mouse does not readily produce a significant amount of an A β -associated protein consistent with the molecular weight of a dimer, we were also not able to assess the potency of mouse brain-derived dimers. Unlike the other A β oligomer preparations used, Tg2576 trimers had no significant effect on errors under this cognitive assay.

Synthetic A β was prepared such that soluble assemblies, but not fibrillar aggregates, are readily formed within expected dimensions (Fig. 3a and b). This form of soluble A β oligomers increased both approach and perseveration errors under ALCR. Both types of errors were increased at a concentration of 1.3 μ M. There was no evidence of a concentration–effect relationship under the limited concentrations tested. To our knowledge, this is the first direct experimental evidence of deficits in complex learned behavior under fibril-free soluble synthetic A β ₄₂ oligomers (Dahlgren et al., 2002; Lambert et al., 1998; Stine et al., 2003). Soluble A β oligomers produced from synthetic A β ₄₂ by this method proved equally potent to mouse brain-derived soluble A β assemblies despite differences in biochemical properties (e.g., SDS-stability). Thus, it appears that the conformation, derivation, and size of the A β molecule may be important when comparing potency.

There is little conclusive information currently available about the exact conformation of the A β assemblies tested in the present study. Certainly, low molecular weight soluble A β derived from recombinant A β contains only protein from that sequence, but comparison of the SDS-PAGE analysis (Fig. 3a) with that of the AFM analysis (Fig. S2) shows significant differences in A β species detected under the two analyses. After 24 h incubation, the AFM clearly shows defined structural A β assemblies not seen at $t=0$. These differences are not reflected in the Western blot (Fig. 3a), which

looks comparable at 0 and 24 h A β incubation. Whether via reduction to dimers, trimers and tetramers as seen under SDS-PAGE or through formation of larger defined A β assemblies as seen under AFM, the exact solution characteristics of the synthetic soluble A β remains undetermined. Similarly tentative is the assumption that cell-produced A β assemblies, with estimated molecular weights that correspond to what would be low-*n* oligomers, are indeed multiples of monomeric A β . In the same way, the precise number of monomeric A β units forming A β *56 has not yet been established. Therefore, it will be important to fully characterize these A β species, especially in comparison to those derived from brains of humans suffering from AD, to insure we are investigating compounds relevant to the human disease.

It should be noted that the exact number of oligomers of a particular size, e.g., dimers, trimers, etc., in the injected solutions is estimated in the current study. If the injected solution contained enough A β to affinity purify and fractionate by SEC, we proceeded with estimates of relative concentrations of oligomers using dot blot, Western blot and BCA analysis (see Fig. 4). However, 7PA2 conditioned media could not be subjected to these analyses because current detection techniques are insensitive at A β protein concentrations below 0.1 μ M. Because the amounts of low-*n* A β oligomers are at least 100 times lower than those estimated for A β *56 and A β trimers following purification, it is not currently possible to detect any variation of wavelength during the live monitoring of A280/A229/A214 nm or by using a BCA assay in regard to these A β solutions. Synthetic A β oligomers in the current study were derived from initially pure preparations containing only the A β ₄₂ peptide and were given at concentrations that could yield estimates of oligomeric molecular weight and thus relative concentration. However, the exact solution characteristics, molecular stoichiometries, and moles of A β oligomers remains imprecise for several reasons. First, no current A β antibody is specific for low-*n* oligomers and antibodies that can reliably detect large-*n* A β oligomers may also detect other non-A β proteins. Second, analysis of A β can change its assembly state as was demonstrated for synthetic A β oligomers under SDS-PAGE and Western blot. Third, total protein assays currently available (e.g., ELISA) only reliably detect the monomer of A β not oligomers (Morishima-Kawashima and Ihara, 1998; Walsh et al., 2002; Sten et al., 2005). Finally, the fate of all A β assemblies once they are injected *in vivo* is unknown. They may be biologically modified or have barriers to brain compartment penetration or absorption. Thus, the differential effect of various A β types only reflect the concentrations and assembly at the time of injection and do not necessarily reflect on the actual potency at a particular brain target.

In summary, both cell-derived and chemically produced soluble A β assemblies were capable of disrupting learned performance under the ALCR assay. Of the brain-derived or synthetic soluble A β assemblies, the product that eluted at 56 kDa under SEC, A β *56, showed some evidence of a direct positive relationship between cognitive deficits and the con-

centrations tested. Perhaps one of the most striking findings from the current study was the remarkable potency of A β derived from 7PA2 cultured cell medium. This form of soluble A β was at least 100 times more potent at producing errors as any of the other forms of A β , regardless of source or size. The reason for such a large difference in potency is currently unknown, but based on our behavioral analysis of this material, it seems likely 7PA2 CM-derived A β has a fundamentally different composition or has different properties of dispersion, absorption or target interaction area than the other types of soluble A β oligomers studied. While multiple assembly forms of soluble A β have cognitive disrupting properties under experimental conditions, this does not prove they are equally involved in the etiology of AD or its symptoms. Effective therapeutic interventions will benefit from identification and characterization of A β assemblies likely present and active in human brain.

Conflict of interest

There are no conflicts of interest for any author.

Acknowledgments

Antibodies 2G3 and 21F12 were generously supplied by Drs. D. Schenk and P. Seubert, Elan Pharmaceuticals, Inc. Dr. Cleary was funded under an ETS Walton Award from Science Foundation Ireland at Trinity College Dublin, Dublin, Republic of Ireland.

Support and disclosure: We gratefully acknowledge support from NIH RO1 AG19121 (MJL), Alzheimer's Association NIRG-06-26957 (CY, JPC), Science Foundation of Ireland (JPC), and NIH 1F32 AG030256-01 (LMJ), and Wellcome Trust Grant 067660 (DMW). ATW is a recipient of EU Early Training Fellowship.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.neurobiolaging.2009.11.007](https://doi.org/10.1016/j.neurobiolaging.2009.11.007).

References

- Bitan, G., Fradinger, E.A., Spring, S.M., Teplow, D.B., 2005. Neurotoxic protein oligomers: what you see is not always what you get. *Amyloid* 12 (2), 88–95.
- Cleary, J.P., Walsh, D.M., Hofmeister, J.J., Shankar, G.M., Kuskowski, M.A., Selkoe, D.J., Ashe, K.H., 2005. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. *Nat. Neurosci.* 8 (1), 79–84.
- Chen, Y.R., Glabe, C.G., 2006. Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides abeta40 and abeta42:

- stable trimer or tetramer formation by aveta42. *J. Biol. Chem.* 281 (34), 24414–24422.
- Dahlgren, K.N., Manelli, A.M., Blaine Stine Jr., W., Baker, L.K., Krafft, G.A., Ladu, M.J., 2002. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. *J. Biol. Chem.* 277 (35), 32046–32053.
- Hepler, R.W., Grimm, K.M., Nahas, D.D., Breese, R., Dodson, E.C., Acton, P., Keller, P.M., Yeager, M., Wang, H., Shughrue, P., Kinney, G., Joyce, J.G., 2006. Solution state characterization of amyloid beta-derived diffusible ligands. *Biochemistry* 45 (51), 15157–15167.
- Hsiao, K., 1996. Correlative memory deficits, A β elevation, and amyloid plaques in transgenic mice. *Science* 274, 99–102.
- Koo, E.H., Squazzo, S.L., 1994. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. *J. Biol. Chem.* 269 (26), 17386–17389.
- Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Roxovsky, I., Trommer, B., Viola, K.L., Wals, P., Zhang, C., Finch, C.E., Krafft, G.A., Klein, W.L., 1998. Diffusible, nonfibrillar ligands derived from A β 1–42 are potent central nervous system neurotoxins. *Proc. Natl. Acad. Sci. U.S.A.* 95, 6448–6453.
- Lesné, S., Koh, M.T., Kotilinek, L., Kaye, R., Glabe, C.G., Yang, A., Gallagher, M., Ashe, K.H., 2006. A specific amyloid-beta protein assembly in the brain impairs memory. *Nature* 440 (7082), 352–357.
- Manelli, A.M., Bulfinch, L.C., Sullivan, P.M., LaDu, M.J., 2007. Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. *Neurobiol. Aging* 28 (8), 1139–1147.
- Mattson, M.P., Cheng, B., Culwell, A.R., Esch, F.S., Lieberburg, I., Rydel, R.E., 1993. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the [beta]-amyloid precursor protein. *Neuron* 10 (2), 243–254.
- Morishima-Kawashima, M., Ihara, I., 1998. The presence of amyloid b-protein in the detergent-soluble membrane compartment of human neuroblastoma cells. *Biochemistry* 37 (44), 15247–15253.
- O'Hare, E., Levine, A.S., Semotuk, M.T., Tierney, K.J., Shephard, R.A., Grace, M.K., Cleary, J., 1996. Utilization of a novel model of food reinforced behavior involving neuropeptide Y, insulin, 2-deoxy-D-glucose and naloxone. *Behav. Pharmacol.* 7 (8), 742–753.
- Podlisny, M.B., Ostaszewski, B.L., Squazzo, S.L., Koo, E.H., Rydel, R.E., Teplow, D.B., Selkoe, D.J., 1995. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. *J. Biol. Chem.* 270 (16), 9564–9570.
- Richardson, R.L., Kim, E.M., Shephard, R.A., Gardiner, T., Cleary, J., O'Hare, E., 2002. Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1–42) injections in the rat. *Brain Res.* 954 (1), 1–10.
- Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., Regan, C.M., Walsh, D.M., Sabatini, B.L., Selkoe, D.J., 2008. Amyloid- β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat. Med.* advanced online publication.
- Stenh, C., Englund, H., Lord, A., Johansson, A., Almeida, C.G., Gellerfors, P., Greengard, P., Gouras, G.K., Lannfelt, L., Nilsson, L.N., 2005. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. *Ann. Neurol.* 58 (1), 147–150.
- Stine, W.B., Dahlgren, K.N., Krafft, G.A., Ladu, M.J., 2003. In vitro characterization of conditions for amyloid- β peptide oligomerization and fibrillogenesis. *J. Biochem.* 278 (13), 11612–11622.
- Townsend, M., Cleary, J.P., Mehta, T., Hofmeister, J., Lesné, S., O'Hare, E., Walsh, D.M., Selkoe, D.J., 2006a. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. *Ann. Neurol.* 60 (6), 668–676.
- Townsend, M., Shankar, G.M., Mehta, T., Walsh, D.M., Selkoe, D.J., 2006b. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. *J. Physiol.* 572 (Pt 2), 477–492.
- Trommer, B.L., Shah, C., Yun, S.H., Gamkrelidze, G., Pasternak, E.S., Stine, W.B., Manelli, A., Sullivan, P., Pasternak, J.F., LaDu, M.J., 2005. ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1–42. *Neurobiol. Dis.* 18 (1), 75–82.
- Walsh, D.M., Tseng, B.P., Rydel, R.E., Podlisny, M.B., Selkoe, D.J., 2000. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. *Biochemistry* 39 (35), 10831–10839.
- Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., Selkoe, D.J., 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* 416 (6880), 535–539.
- Walsh, D.M., Klyubin, I., Shankar, G.M., Townsend, M., Fadeeva, J.V., Betts, V., Podlisny, M.B., Cleary, J.P., Ashe, K.H., Rowan, M.J., Selkoe, D.J., 2005. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. *Biochem. Soc. Trans.* 33 (Pt 5), 1087–1090.
- Walsh, D.M., Selkoe, D.J., 2007. A beta oligomers—a decade of discovery. *J. Neurochem.* 101 (5), 1172–1184.
- Wang, Q., Walsh, D.M., Rowan, M.J., Selkoe, D.J., Anwyl, R., 2004. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. *J. Neurosci.* 24 (13), 3370–3378.
- Yun, S.H., Gamkrelidze, G., Stine, W.B., Sullivan, P.M., Pasternak, J.F., Ladu, M.J., Trommer, B.L., 2006. Amyloid-beta1–42 reduces neuronal excitability in mouse dentate gyrus. *Neurosci. Lett.* 403 (1–2), 162–165.